These observations lay the ground for future follow-up studies on the involvement of Egr1, B2m, and Klf6 gene products in AD pathogenesis and progression, and exploring the effects of pharmacological inhibition and activation of these target proteins on AD pathology. Here, B2M is linked to Alzheimer disease.